August 24, 2016 03:38 PM EDTUpdated September 12, 06:08 PM
Bioregnum
R&D
Opinion

Biotech has a bad day af­ter politi­cos pounce on an­oth­er drug pric­ing scan­dal

Call it the Hillary ef­fect. Or Mar­tin Shkre­li on steroids.

The Nas­daq biotech stock in­dex slid 3.5% Wednes­day af­ter­noon af­ter the tsuna­mi of pub­lic …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

Mer­ck fi­nal­ly has sub­cu­ta­neous Keytru­da re­sults, and it's go­ing to reg­u­la­tors

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times